Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SEP-225289: Phase II data

Preliminary results from a Phase II trial in 514 patients showed SEP-225289 missed the primary endpoint of a reduction

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE